Abstract. Antioxidative flavonoids are used to reduce the risk of cardiovascular diseases in humans. However, the precise mechanism for the anti-atherosclerotic actions of flavonoids remains to be elucidated. In the present study, to assess the mechanism for the action of antioxidative flavonoids on atherosclerosis, we investigated the effect of flavangenol, one of the most potent antioxidants currently known, on spontaneously hyperlipidemic B6.KOR-Apoe shl mice. Flavangenol was orally administered to B6.KORApoe shl mice ad libitum (6 mg flavangenol/mouse/day). After 6 months, serum levels of lipids (total cholesterol, triglyceride, HDL-cholesterol and LDL-cholesterol) and lipid peroxide were measured, and histopathological changes (lipid accumulation and inflammatory cell infiltration) in the aortic root were evaluated. Serum levels of total cholesterol and LDL-cholesterol were markedly increased, and HDLcholesterol levels were decreased in B6
Introduction
Hypercholesterolemia, diabetes and tobacco are risk factors for the pathogenesis of atherosclerosis (1) . In addition to these established risk factors, epidemiological studies have indicated that increased oxidative stress is also involved in atherosclerosis (2) (3) (4) . Atherosclerosis lesions develop from a focal accumulation of lipoproteins and monocyte-derived macrophages within the wall of arterial blood vessels (5) . Within the lesions, intimal macrophages promote the accumulation of cholesterol. The source of this cholesterol is lipoprotein particles that pass from the blood into the vessel wall and are subsequently modified by oxidation (5) .
Flavangenol ® , also known as Pycnogenol ® , is a pine bark extract of the French maritime pine (Pinus pinaster) with a mixture of flavonoids, which are mainly compounds of proanthocyanidin containing the polyhydroxy flavan-3-ol unit in di-and tetra-form (6) . Flavangenol is one of the most potent antioxidants currently known and is much more potent than the antioxidative vitamins C and E (6, 7) . In addition, flavangenol has antiplatelet and endothelial protective activities (8, 9) . Of importance, flavangenol administration suppresses the development of atherosclerotic lesions in apolipoprotein E (ApoE)-knockout (KO) mice (10) . Similarly, tea catechin and potato anthocyanins with antioxidative activities have been reported to suppress the formation of atherosclerotic lesions in ApoE-KO mice (11, 12) . Thus, antioxidative flavonoids are used to reduce the risk of cardiovascular diseases in humans (13) (14) (15) (16) . Genetic analysis revealed gross disruption of the Apoe gene (a gene for ApoE) in KOR-Apoe shl , and SHL mice exhibit severe hypercholesterolemia (>1000 mg/dl) and develop atherosclerotic lesions, along with severe skin xanthoma. When compared with ApoE-KO mice, in which the Apoe gene has been disrupted by homologous recombination, cholesterol levels were much higher, but yet atherosclerotic lesions were less severe in SHL mice (17) . Furthermore, three lines of congenic mice were established with a genetic background of C57BL/6, BALB/c or C3/He (17) . Among SHL and congenic SHL mice, B6.KOR-Apoe shl mice exhibit the least severe hypercholesterolemia but develop the most severe atherosclerotic lesions (17) .
In the present study, to elucidate the mechanism for the antioxidative actions of flavonoids on atherosclerosis, we investigated the effect of flavangenol, one of the most potent antioxidants currently known, on B6.KOR-Apoe shl mice by evaluating serum levels of lipids (such as total cholesterol, HDL-cholesterol, LDL-cholesterol and triglyceride) and lipid peroxide as well as histopathological changes (lipid accumulation and inflammatory cell infiltration) in the aortic root.
Materials and methods
Animal model. All procedures were carried out according to the Institutional Animal Care and Committee Guide of the Juntendo University School of Medicine. Male B6.KORApoe shl mice and C57BL/6 mice (8-week-old; Japan SLC, Shizuoka, Japan) were used in the present study. Three mice per cage were housed under specific pathogen-free conditions (controlled temperature of 24±3˚C and humidity of 55±15%) and fed standard laboratory food ad libitum. Flavangenol ® was supplied by Toyo Shinyaku Co., Ltd. (Saga, Japan). Flavangenol was dissolved in tap water (1 mg/ml) and orally administered to B6.KOR-Apoe shl mice ad libitum for 6 months. The intake volume of flavangenol solution was measured once a week, and it was found that the animals received an average of 6 ml flavangenol solution (6 mg flavangenol/mouse/day).
Mice were divided into three groups; the C57BL/6 control group (C57BL/6; n=3), the B6.KOR-Apoe shl group without flavangenol (B6.KOR-Apoe shl ; n=3) and the B6.KOR-Apoe shl group with flavangenol (+Flavangenol; n=3). All groups of mice were allowed to move freely in aluminum cages. Animals were sacrificed after 6 months.
Tissue preparation and histopathological evaluation. Mice were sacrificed by collecting blood from the inferior vena cava. Vasculature was perfused with phosphate-buffered saline (PBS; 30 ml) and 10% formalin in PBS (30 ml). The aortic root was dissected under a microscope and frozen in optimal cutting temperature (OCT) embedding medium (Sakura Finetechnical, Co., Ltd., Tokyo, Japan 
Results
Evaluation of serum lipids. First, we evaluated the effect of flavangenol administration on serum lipid levels. Serum total cholesterol levels were 62.8±17.3 mg/dl in C57BL/6 mice, and markedly increased in B6.KOR-Apoe shl mice (625.8± 94.8 mg/dl) (p<0.001); flavangenol administration did not affect total cholesterol levels (617.2±88.8 mg/dl) (Fig. 1A) . Similarly, serum LDL-cholesterol levels were significantly increased in B6.KOR-Apoe shl mice (586.6±71.8 mg/dl) compared to C57BL/6 mice (2.9±1.2 mg/dl) (p<0.001); however, flavangenol administration did not have an effect on LDL-cholesterol levels (569.2±73.3 mg/dl) (Fig. 1B) . In contrast, there were no significant differences in serum triglyceride levels among C57BL/6 mice (98.8±8.3 mg/dl), B6.KOR-Apoe shl mice (193.9±64.1 mg/dl) and flavangenoladministered mice (157.4±50.7 mg/dl) (Fig. 1C) . Of note, serum HDL-cholesterol levels were significantly decreased in B6.KOR-Apoe shl mice (16.9±2.3 mg/dl) compared to C57BL/6 mice (53.7±6.9 mg/dl) (p<0.001), but were slightly increase by flavangenol administration (+Flavangenol; 22.0±1.7 mg/dl, p<0.05) (Fig. 1D) .
Thus, total cholesterol and LDL-cholesterol levels markedly increased and HDL-cholesterol levels decreased in B6.KOR-Apoe shl compared to C57BL/6 control mice. Among these serum lipids, only HDL-cholesterol levels were significantly increased by flavangenol administration.
Effect of flavangenol administration on histopathological changes in atherosclerotic lesions. Next, we evaluated the effect of flavangenol administration on the histopathological changes of the atherosclerotic lesion in the aortic root by staining sections with Oil Red O and counting infiltrated cells in the atherosclerotic lesion. It has been reported that B6.KOR-Apoe shl mice spontaneously develop atherosclerotic lesions in the aortic root (13) . Consistent with this, Oil Red O staining (i.e., lipid accumulation) was significantly increased in B6.KOR-Apoe shl mice compared to C57BL/6 mice ( Fig. 2A , B and D) (p<0.001). Flavangenol administration significantly suppressed the increase of Oil Red O staining (Fig. 2C and  D) (p<0.01) . Similarly, inflammatory cell infiltration into the intimal and subintimal layers was significantly increased in B6.KOR-Apoe shl mice compared to C57BL/6 mice (Fig. 3A , B and D) (p<0.01). Importantly, flavangenol administration significantly suppressed the increase in inflammatory cell infiltration ( Fig. 3C and D) (p<0.01) .
Thus, flavangenol exhibits an anti-atherosclerotic action in B6.KOR-Apoe shl mice by suppressing lipid accumulation and inflammatory cell infiltration.
Effect of flavangenol administration on serum lipid peroxide level.
Oxidative stress is associated with the pathogenesis of atherosclerosis (18) . Thus, we evaluated the effect of flavangenol administration on serum lipid peroxide levels by the TBARS assay. The serum lipid peroxide levels were 9.2±0.6 nmol/ml in C57BL/6 mice, and markedly increased in B6.KOR-Apoe shl mice (41.2±3.1 nmol/ml). Of note, flavangenol administration significantly reduced serum lipid peroxide levels in B6.KOR-Apoe shl mice (32.6±3.4 nmol/ml) (Fig. 4) . These observations indicate that flavangenol administration suppresses the lipid peroxidation in B6.KORApoe shl mice.
Discussion
In the early stages of cardiovascular disease progression, endothelial dysfunction triggers a chronic inflammatory process in the vessel wall. Induction of adhesion molecules in endothelial cells facilitates the adhesion of monocytic leukocytes, trapping them and allowing their transmigration through the endothelial layer into the underlying intima. There they become tissue macrophages and subsequently foam cells following the uptake of oxidatively-modified lipids (19, 20) . It is generally accepted that antioxidative flavonoids reduce the risk of cardiovascular diseases in humans (12, 13) . However, the precise mechanism for the anti-atherosclerotic actions of flavonoids remains to be elucidated. Flavangenol is known to be one of the most potent antioxidants. In addition, flavangenol has antiplatelet and endothelial protective activities (8, 9) . In this study, to elucidate the mechanism of the antioxidative effects of flavonoids on atherosclerosis, we investigated the effect of flavangenol, on SHL and atherosclerotic B6.KOR-Apoe shl mice by evaluating serum levels of lipids and lipid peroxide as well as histopathological changes in the aortic root. B6.KOR-Apoe shl mice are apolipoprotein E-deficient, and their dyslipidemic phenotypes, including their high plasma lipoprotein cholesterol levels and atherosclerosis, have been described by Matushima et al (16, 17) . The present study confirmed that B6.KOR-Apoe shl mice exhibit much higher levels of serum total cholesterol, triglyceride, LDL-cholesterol and lipid peroxide but lower levels of HDL-cholesterol than C57BL/6 mice used as a control. In addition, B6.KORApoe shl mice show a significant increase of Oil Red O staining and exhibit augmented inflammatory cell infiltration into the intimal and subintimal layers of the aortic root, compared to C57BL/6 mice.
Dyslipidemia (hyperlipidemia) is one of the most important modifiable risk factors for cardiovascular diseases (21, 22) . Thus, we examined the effect of flavangenol administration on the dyslipidemia observed in B6.KORApoe shl mice. Flavangenol administration did not have a significant effect on the increased levels of serum total cholesterol, triglyceride and LDL-cholesterol. In contrast, flavangenol administration slightly but significantly increased the reduced level of HDL-cholesterol. It has already been shown that HDL-cholesterol levels are inversely correlated with the risk of cardiovascular diseases, because increases in HDL-cholesterol decrease the risk of developing atherosclerosis (23) . Thus, flavangenol is likely to suppress the development of atherosclerosis in B6.KOR-Apoe shl mice by increasing HDL-cholesterol levels.
Oxidative stress is a risk factor for the development of cardiovascular disease, and it is involved in the pathogenesis and development of atherosclerosis (18) . Lipid peroxidation, such as production of oxidative LDL-cholesterol, may occur under the conditions of hyperlipidemia, and oxidized substances, such as oxidized LDL-cholesterol, trigger inflammatory actions on endothelial cells and macrophages, and accelerate the progression of atherosclerosis (24) . Of note, flavangenol administration significantly reduced the level of lipid peroxidation measured as TBARS, which is routinely assayed for the oxidative modification of LDL. Thus, flavangenol can reduce the oxidative stress (lipid peroxidation) and exhibit a suppressive action on the formation of atherosclerotic lesions in B6.KOR-Apoe shl mice.
Atherosclerosis is considered to be a chronic inflammatory disease, which is characterized by lipid accumulation and infiltration of mononuclear leukocytes into the intima (23) . In the present study, flavangenol administration not only reduced the area of Oil Red O-stained atherosclerotic lesions but also suppressed the infiltration of monocytic cells into the intima (chronic inflammation) in the aortic root of B6.KORApoe shl mice. These observations indicate that flavangenol represses the formation of atherosclerotic lesions (lipid accumulation) as well as the chronic inflammation of the vessel wall in dyslipidemia.
As for the effects on the atherosclerotic animal models, flavangenol administration (4.5 g food intake containing 2% flavangenol, 90 mg flavangenol/day/mouse for 9 weeks) has been reported to suppress the atherosclerotic lesions without changing the levels of TBARS and other serum lipids except total cholesterol in ApoE-KO mice (10) . In contrast, the present study has revealed that flavangenol administration (6 ml of 1 mg/ml flavangenol solution, 6 mg flavangenol/day/mouse for 6 months) suppresses the atherosclerotic lesions accompanied with a significant increase of HDL-cholesterol and decrease of TBARS in B6.KOR-Apoe shl mice. The dissimilar effects of flavangenol between the two studies may be explained by the differences in the doses (90 mg vs. 6 mg), durations (9 weeks vs. 6 months), delivery methods (food intake vs. drinking) and mouse strains (ApoE-KO vs. B6.KORApoe shl ) used. Collectively, the present study has provided evidence that flavangenol, one of the most potent antioxidants, exerts an anti-atherosclerotic action on SHL and atherosclerotic B6.KOR-Apoe shl mice, possibly by increasing HDL-cholesterol levels and reducing lipid peroxide levels, thereby suppressing lipid accumulation (formation of atherosclerotic lesion) and inflammatory cell infiltration (chronic inflammation) in the intima of the aortic root. The effect of flavangenol on human atherosclerotic disorders and its mechanism should be further evaluated in the future. 
